Short answer · Medically reviewed summary · Last updated: 2026-04-06
Progressive Supranuclear Palsy was first formally described as a distinct clinical entity in 1964 by neurologists John Clifford Richardson, Jerzy Olszewski, and John Steele, who identified the condition through a study of eight patients presenting with unique movement and ocular symptoms. From Clinical Observation to Pathological Understanding Before the landmark 1964 paper, patients with Progressive Supranuclear Palsy were often misdiagnosed with Parkinson’s disease or other forms of atypical parkinsonism. The researchers identified that the core features—specifically the "supranuclear" gaze palsy (difficulty moving the eyes voluntarily) and postural instability—distinguished it from more common motor disorders.
3 people with Progressive Supranuclear Palsy have shared their first-person experience on this question at DiseaseMaps.
What is the history of Progressive Supranuclear Palsy?
History of Progressive Supranuclear Palsy: when and how it was discovered, and the milestones in research since, medically reviewed.
Progressive Supranuclear Palsy was first formally described as a distinct clinical entity in 1964 by neurologists John Clifford Richardson, Jerzy Olszewski, and John Steele, who identified the condition through a study of eight patients presenting with unique movement and ocular symptoms.
From Clinical Observation to Pathological Understanding
Before the landmark 1964 paper, patients with Progressive Supranuclear Palsy were often misdiagnosed with Parkinson’s disease or other forms of atypical parkinsonism. The researchers identified that the core features—specifically the "supranuclear" gaze palsy (difficulty moving the eyes voluntarily) and postural instability—distinguished it from more common motor disorders. Throughout the 1970s and 1980s, the focus shifted to neuropathology, revealing the accumulation of tau protein aggregates in the brain, which remains a cornerstone of our modern understanding of the disease.
Evolution of Diagnosis and Advocacy
Historically, the diagnosis of Progressive Supranuclear Palsy was primarily retrospective, often confirmed only during autopsy. However, the development of sophisticated neuroimaging, such as the "hummingbird sign" on MRI, has revolutionized our ability to identify the disease in living patients. As medical awareness grew, so did the necessity for patient advocacy. Organizations like CurePSP have been instrumental in transforming the landscape for families, moving the focus from mere symptom management to a concerted global effort to fund research into disease-modifying therapies.
Modern Scientific Progress
Our grasp of Progressive Supranuclear Palsy has been deepened by genetic research, which has identified links to the MAPT gene. While we have not yet discovered a cure, the shift toward understanding Progressive Supranuclear Palsy as a "tauopathy"—a protein-misfolding disorder—has opened new pathways for clinical trials targeting the underlying biology rather than just the physical symptoms. This historical transition from observing outward tremors to analyzing molecular misfolding marks the most significant leap in the history of Progressive Supranuclear Palsy.
Medical Disclaimer: This information is for educational purposes and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult with a neurologist or specialist regarding your specific medical condition.
References
- CurePSP (Foundation for PSP/CBD and Related Brain Diseases)
- NIH Genetic and Rare Diseases Information Center (GARD)
- Orphanet: The portal for rare diseases and orphan drugs
- Online Mendelian Inheritance in Man (OMIM)
Posted Aug 12, 2017 by Diana Sanders 2000
Posted Sep 24, 2021 by matina 2610
Posted Nov 8, 2017 by Maria Veronica Ortiz Solís 2000
